![](https://investorshub.advfn.com/uicon/430307.png?cb=1612906370)
Thursday, December 19, 2019 1:42:15 PM
“AbbVie Inc. ABBV announced that the European Commission has granted approval to its JAK inhibitor, Rinvoq (upadacitinib) for the treatment of moderate-to-severe rheumatoid arthritis (“RA”) in patients who experience inadequate response or are intolerant to disease-modifying anti-rheumatic drugs (DMARDs). The drug is approved as a monotherapy or in combination with methotrexate in this patient population.
Please note that the JAK inhibitor had received approval for a similar indication in the United States in August and the early uptake trends of the drug have been encouraging.Rinvoq has generated sales of $14 million in the third quarter since its approval.
Shares of AbbVie have gained 14% in the past six months compared with the industry’s increase of 6%.
The approval for Rinvoq in Europe was based on encouraging data from the phase III SELECT program, which evaluated more than 4000 patients across five phase III studies on RA. In all studies, the drug met every primary and secondary endpoint. Data from the studies under the SELECT program demonstrated that Rinvoq alone or in combination with conventional synthetic DMARDs improved rates of low disease activity and clinical remission in RA patients compared to placebo, MTX or AbbVie’s blockbuster inflammatory drug, Humira (adalimumab).
Humira is the primary revenue generator for AbbVie with global sales of more than $14 billion in the first nine months of 2019. However, the drug’s sales declined significantly in Europe due to the launch of several biosimilars last year from companies including Amgen AMGN, Biogen BIIB and Novartis NVS. Moreover, the drug is set to lose patent protection in the United States, beginning 2023. A similar decline in U.S. sales for the drug will significantly dent AbbVie’s revenues going forward.
We expect Rinvoq and AbbVie’s another new inflammation drug, Skyrizi, to partially offset lost sales for Humira over the long term. However, Humira is approved for 10 different inflammatory indications. AbbVie’s efforts to expand labels of Skyrizi and Rinvoq will further reduce the impact of patent loss for Humira on its revenues, if successful.
In a separate event, the company has reportedly entered into an agreement with the pan-Canadian Pharmaceutical Alliance for the commercialization of Venclexta in combination with J&J’s Rituxan (rituximab) as a treatment for chronic lymphocytic leukemia in second or later-line setting.”
https://finance.yahoo.com/news/abbvies-jak-inhibitor-rinvoq-receives-150103062.html
Recent ABBV News
- AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis • PR Newswire (US) • 07/12/2024 12:30:00 PM
- AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer • PR Newswire (US) • 07/10/2024 12:00:00 PM
- Tesla Listed for China’s Government Vehicles; Macy’s Acquisition Offer Raised, and More News • IH Market News • 07/05/2024 12:13:34 PM
- AbbVie to Host Second-Quarter 2024 Earnings Conference Call • PR Newswire (US) • 07/02/2024 12:00:00 PM
- Robert A. Michael Assumes Role as AbbVie Chief Executive Officer • PR Newswire (US) • 07/01/2024 12:00:00 PM
- AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma • PR Newswire (US) • 06/28/2024 06:00:00 AM
- AbbVie Acquires Celsius Therapeutics • PR Newswire (US) • 06/27/2024 01:26:00 PM
- Introducing Allē Payment Plans, Powered by Cherry • PR Newswire (US) • 06/27/2024 12:30:00 PM
- U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma • PR Newswire (US) • 06/26/2024 11:03:00 PM
- AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) • PR Newswire (US) • 06/25/2024 12:15:00 PM
- AbbVie Declares Quarterly Dividend • PR Newswire (US) • 06/21/2024 12:00:00 PM
- AbbVie Appoints Roxanne S. Austin as Lead Independent Director of the Board of Directors • PR Newswire (US) • 06/20/2024 12:00:00 PM
- U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease • PR Newswire (US) • 06/18/2024 10:18:00 PM
- AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer • PR Newswire (US) • 06/14/2024 08:08:00 PM
- AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease • PR Newswire (US) • 06/13/2024 11:59:00 AM
- BOTOX® Cosmetic (onabotulinumtoxinA) Reveals 2024 Women Entrepreneur Grant Recipients • PR Newswire (US) • 06/11/2024 12:00:00 PM
- AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer • PR Newswire (US) • 06/06/2024 12:45:00 PM
- SkinMedica® Celebrates 25 Years of Empowering Radiant Skin • PR Newswire (US) • 06/06/2024 12:30:00 PM
- AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers • PR Newswire (US) • 06/06/2024 12:00:00 PM
- AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383 • PR Newswire (US) • 06/05/2024 01:00:00 PM
- RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis • PR Newswire (US) • 06/04/2024 12:30:00 PM
- Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50 • PR Newswire (US) • 06/04/2024 12:05:00 PM
- AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare Conference • PR Newswire (US) • 06/03/2024 12:30:00 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/31/2024 08:05:10 PM
- AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis • PR Newswire (US) • 05/31/2024 06:00:00 AM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM